Journal
APPLIED MATERIALS TODAY
Volume 11, Issue -, Pages 136-143Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.apmt.2018.01.008
Keywords
Hydrogen therapy; Controlled release; Drug delivery; Mesoporous silica nanoparticles; Anticancer
Categories
Funding
- National Natural Science Foundation of China [81701827]
- Shenzhen Basic Research Program [JCYJ20170302151858466]
- Shenzhen Peacock Plan [KQTD2016053112051497]
- Natural Science Foundation of SZU [827-000143]
- Fundamental Research Funds for the Shenzhen University, China [2016076]
- State Key Laboratory of Advanced Technology for Materials Synthesis and Processing
- Wuhan University of Technology [2017-KF-6]
Ask authors/readers for more resources
Hydrogen gas therapy as an emerging and promising therapy strategy has overwhelming advantages especially in bio-safety compared with other gas therapy routes, but is facing a great challenge in the long-term, highly-concentrated, deeply-seated disease site-specific administration of hydrogen gas, owing to its low solubility, high but aimless diffusibility in vivo. Herein, we propose to construct an ammonia borane-loaded mesoporous silica nanomedicine (AB@MSN) to realize the intratumoral high-payload delivery and in situ acid-controlled release of hydrogen gas. The constructed AB@MSN nanomedicine has a superhigh H-2 loading capacity (130.6 mg/g, more than 1370 times higher than that of the traditional H-2@liposome nanomedicine) and a highly acid-responsive sustained release behavior, exhibiting high anticancer efficacies and high bio-safety in vitro and in vivo. The proposed nanomedicine-based strategy opens a new window for precision high-efficacy hydrogen therapy. (C) 2018 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available